Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 528

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Atenolol versus Losartan in Children and Young Adults with Marfan's Syndrome

Open access
Lacro, Ronald V., Dietz, Harry C., Sleeper, Lynn A., Yetman, Anji T., Bradley, Timothy J., Colan, Steven D., Pearson, Gail D., Selamet Tierney, E. Seda, Levine, Jami C., Atz, Andrew M., Benson, D. Woodrow, Braverman, Alan C., Chen, Shan, De Backer, Julie, Gelb, Bruce D., Grossfeld, Paul D., Klein, Gloria L., Lai, Wyman W., Liou, Aimee, Loeys, Bart L., Markham, Larry W., Olson, Aaron K., Paridon, Stephen M., Pemberton, Victoria L., Pierpont, Mary Ella, Pyeritz, Reed E., Radojewski, Elizabeth, Roman, Mary J., Sharkey, Angela M., Stylianou, Mario P., Wechsler, Stephanie Burns, Young, Luciana T., Mahony, Lynn · 2014 · New England Journal of Medicine

Abstract

BACKGROUND: Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. METHODS: We conducted a randomized trial comparing losartan with atenolol in children and young adults with Marfan's syndrome. The primary outcome was the rate of aortic-root enlargement, expressed as the change in the maximum aortic-root-diameter z score indexed to body-surface area (hereafter, aortic-root z score) over a 3-year period. Secondary outcomes included the rate of change in the absolute diameter of the aortic root; the rate of change in aortic regurgitation; the time to aortic dissection, aortic-root surgery, or death; somatic growth; and the incidence of adverse events. RESULTS: From January 2007 through February 2011, a total of 21 clinical centers enrolled 608 participants, 6 months to 25 years of age (mean [±SD] age, 11.5±6.5 years in the atenolol group and 11.0±6.2 years in the losartan group), who had an aortic-root z score greater than 3.0. The baseline-adjusted rate of change in the mean (±SE) aortic-root z score did not differ significantly between the atenolol group and the losartan group (-0.139±0.013 and -0.107±0.013 standard-deviation units per year, respectively; P=0.08). Both slopes were significantly less than zero, indicating a decrease in the aortic-root diameter relative to body-surface area with either treatment. The 3-year rates of aortic-root surgery, aortic dissection, death, and a composite of these events did not differ significantly between the two treatment groups. CONCLUSIONS: Among children and young adults with Marfan's syndrome who were randomly assigned to losartan or atenolol, we found no significant difference in the rate of aortic-root dilatation between the two treatment groups over a 3-year period. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00429364.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1404731

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 528

Metadata

Authors
Lacro, R. V., Dietz, H. C., Sleeper, L. A., Yetman, A. T., Bradley, T. J., Colan, S. D., Pearson, G. D., Selamet Tierney, E. S., Levine, J. C., Atz, A. M., Benson, D. W., Braverman, A. C., Chen, S., De Backer, J., Gelb, B. D., Grossfeld, P. D., Klein, G. L., Lai, W. W., Liou, A., Loeys, B. L., Markham, L. W., Olson, A. K., Paridon, S. M., Pemberton, V. L., Pierpont, M. E., Pyeritz, R. E., Radojewski, E., Roman, M. J., Sharkey, A. M., Stylianou, M. P., Wechsler, S. B., Young, L. T., & Mahony, L.
Venue
New England Journal of Medicine
Published
2014-11-27
Volume
371
Issue
22
Pages
2061-2071
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2135348048
Cited by
528
References
26
FWCI
35.46
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.